Mode
Text Size
Log in / Sign up
Phase 2 N=358 Randomized Treatment

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

Seizures

Enrolled (actual)
358
Serious AEs
1.1%
Results posted
Oct 2011
Primary outcome: Primary: Length of Seizure After Study Medication Administration — 3.0; 4.3 Minutes

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Midazolam (Drug); Diazepam (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
University of Utah
Primary completion
Dec 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Length of Seizure After Study Medication Administration
3.0; 4.3
SECONDARY
Respiratory Depression Requiring Intubation
1; 0
SECONDARY
Number of Patients Who Needed Additional Medication to Treat the Seizure in the Emergency Department Within 24 Hours
5; 5
SECONDARY
Number of Patients Needed to be Seen or Treated in the Emergency Department for Their Seizure and Use of Study Medication.
21; 17
SECONDARY
Number of Patients That Were Admitted to the Hospital After Their Seizure and Use of Study Medication.
4; 3
SECONDARY
Number of Patients Who Had a Repeat Seizure Within 12 Hours After Their Seizure Who Used Study Medication
1; 1
SECONDARY
Respiratory Depression Requiring Oxygen at Discharge From the Emergency Department.
3; 1

Summary

The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.

Eligibility Criteria

Inclusion Criteria

  • Children seventeen years and under will be identified through a Pediatric Neurology clinic at Primary Children's Medical Center,
  • Known seizure disorder, AND
  • Either have or will be prescribed a rescue anti-epileptic (rectal diazepam, or Diastat) for home use by their neurologist.

Exclusion Criteria

  • The neurologist does not prescribe a rescue medication for home use,
  • 18 years of age or older,
  • They have absence seizures, OR
  • They have been prescribed lorazepam for home use for seizure activity.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00326612). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search